Duke Infective Endocarditis Criteria 3.0 for the Clinician

Correspondence: H. F. Chambers, Department of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110 ([email protected]).

Potential conflicts of interest. H.C. owns stock in Merck and Moderna and was a member of a Data Safety Monitoring Board for Merck. S. E. reports grants from the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), the National Cancer Institute (NCI/NIH), the National Heart, Lung, and Blood Institute (NHLBI/NIH), the Centers for Disease Control and Prevention (CDC), and grants or contracts from Degruyter (Editor-in-Chief: Statistical Communications in Infectious Diseases); book royalties from Taylor & Francis; consulting fees paid to the author from Genentech, AstraZeneca, Takeda, Microbiotix, Johnson & Johnson, Endologix, ChemoCentryx, Becton Dickenson, Atricure, Roivant, Neovasc, Nobel Pharma, Horizon, International Drug Development Institute, SVB Leerink, Medtronic, Regeneron, Wake Forest University, Recor, Janssen, and IDDI; payment or honoraria for Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) (honoraria), the Liver Forum (travel), and the Paris nonalcoholic steatohepatitis Meeting (travel); an honorarium and support for attending meetings and/or travel from the Food and Drug Administration (FDA); paid participation on a Data Safety Monitoring Board or Advisory Board for NIH, Biomedical Advanced Research and Development Authority, Breast International Group, University of Pennsylvania, Washington University, Duke University, Roche, Pfizer, Takeda, Akouos, Apellis, Teva, Vir, DayOneBio, Alexion, Tracon, Rakuten, Abbvie, GSK, Eli Lilly, Nuvelution, Clover, FHI Clinical, Lung Biotech, SAB Biopharm, Advantagene, Candel, and Novartis; and unpaid roles as a Board member for the American Statistical Association, Society for Clinical Trials, and Frontier Science Foundation. S. Z. reports no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Received November 15, 2023

Revised February 28, 2024

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)